Norway Savings Bank Buys 188 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Norway Savings Bank lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,635 shares of the company’s stock after buying an additional 188 shares during the quarter. Norway Savings Bank’s holdings in IDEXX Laboratories were worth $1,826,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Harbour Investments Inc. raised its stake in shares of IDEXX Laboratories by 24.1% in the fourth quarter. Harbour Investments Inc. now owns 108 shares of the company’s stock worth $44,000 after buying an additional 21 shares during the period. RIA Advisory Group LLC grew its position in shares of IDEXX Laboratories by 4.0% during the first quarter. RIA Advisory Group LLC now owns 572 shares of the company’s stock worth $286,000 after purchasing an additional 22 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of IDEXX Laboratories by 10.8% during the first quarter. EverSource Wealth Advisors LLC now owns 236 shares of the company’s stock worth $118,000 after purchasing an additional 23 shares in the last quarter. Pine Haven Investment Counsel Inc grew its position in shares of IDEXX Laboratories by 3.2% during the first quarter. Pine Haven Investment Counsel Inc now owns 782 shares of the company’s stock worth $391,000 after purchasing an additional 24 shares in the last quarter. Finally, First National Bank of Hutchinson grew its position in shares of IDEXX Laboratories by 3.4% during the first quarter. First National Bank of Hutchinson now owns 880 shares of the company’s stock worth $440,000 after purchasing an additional 29 shares in the last quarter. Institutional investors own 86.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on IDXX shares. StockNews.com started coverage on IDEXX Laboratories in a research report on Thursday, August 17th. They set a “buy” rating for the company. Atlantic Securities cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $610.00 target price for the company. in a research report on Wednesday, August 2nd. Stifel Nicolaus cut their target price on IDEXX Laboratories from $525.00 to $500.00 and set a “hold” rating for the company in a research report on Friday. Morgan Stanley raised their price target on IDEXX Laboratories from $590.00 to $600.00 and gave the company an “overweight” rating in a report on Thursday, August 3rd. Finally, JPMorgan Chase & Co. raised their price target on IDEXX Laboratories from $550.00 to $600.00 and gave the company an “overweight” rating in a report on Wednesday, August 2nd. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $571.67.

IDEXX Laboratories Trading Down 2.5 %

Shares of IDXX stock traded down $11.39 on Friday, reaching $450.69. 770,079 shares of the company’s stock were exchanged, compared to its average volume of 452,822. IDEXX Laboratories, Inc. has a 52 week low of $317.06 and a 52 week high of $564.73. The company has a current ratio of 1.33, a quick ratio of 0.89 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $37.41 billion, a PE ratio of 47.84, a P/E/G ratio of 2.66 and a beta of 1.20. The company’s fifty day simple moving average is $510.75 and its 200 day simple moving average is $490.61.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 1st. The company reported $2.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.43 by $0.24. IDEXX Laboratories had a return on equity of 104.84% and a net margin of 22.52%. The firm had revenue of $943.63 million during the quarter, compared to analyst estimates of $927.84 million. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 9.82 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael Lane sold 16,027 shares of IDEXX Laboratories stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $510.00, for a total transaction of $8,173,770.00. Following the completion of the sale, the executive vice president now directly owns 4,034 shares of the company’s stock, valued at approximately $2,057,340. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other IDEXX Laboratories news, EVP James F. Polewaczyk sold 22,909 shares of IDEXX Laboratories stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $510.56, for a total transaction of $11,696,419.04. Following the completion of the sale, the executive vice president now directly owns 10,038 shares of the company’s stock, valued at approximately $5,125,001.28. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael Lane sold 16,027 shares of the business’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $510.00, for a total value of $8,173,770.00. Following the completion of the transaction, the executive vice president now directly owns 4,034 shares of the company’s stock, valued at $2,057,340. The disclosure for this sale can be found here. Insiders sold a total of 52,360 shares of company stock valued at $26,743,411 in the last ninety days. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.